Free tool
FAERS Monitor: Thermazene
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018810 or its brand name (Thermazene, Silver Sulfadiazine). Reports on generic versions are filed under their own applications.
Reports
1,402
Serious
925
66% of reports
Hospitalization
470
Death reported
173
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use in unapproved indication133
- off label use113
- pain95
- chronic kidney disease86
- fatigue84
- drug ineffective77
- death71
- acute kidney injury66
- diarrhoea66
- nausea64
- anxiety62
- pneumonia61
- rash59
- renal failure57
- fall55
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 14 |
| 2006 | 11 |
| 2007 | 16 |
| 2008 | 4 |
| 2009 | 16 |
| 2010 | 13 |
| 2011 | 17 |
| 2012 | 34 |
| 2013 | 22 |
| 2014 | 31 |
| 2015 | 37 |
| 2016 | 79 |
| 2017 | 73 |
| 2018 | 106 |
| 2019 | 116 |
| 2020 | 125 |
| 2021 | 173 |
| 2022 | 126 |
| 2023 | 113 |
| 2024 | 88 |
| 2025 | 85 |
| 2026 | 93 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,757 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 86 | 17.0 | 13.8 | 1,282 |
| product use in unapproved indicationSignal | 133 | 8.1 | 6.9 | 824 |
| acute kidney injurySignal | 66 | 6.5 | 5.1 | 302 |
| renal failureSignal | 57 | 6.4 | 5.0 | 258 |
| anxietySignal | 62 | 3.3 | 2.6 | 97 |
| pneumoniaSignal | 61 | 2.8 | 2.2 | 71 |
| fallSignal | 55 | 2.5 | 1.9 | 48 |
| painSignal | 95 | 2.3 | 1.9 | 72 |
| rashSignal | 59 | 2.0 | 1.6 | 30 |
| off label use | 113 | 1.9 | 1.6 | 52 |
| fatigue | 84 | 1.6 | 1.3 | 20 |
| diarrhoea | 66 | 1.5 | 1.2 | 12 |
| death | 71 | 1.2 | 1.0 | 3 |
| nausea | 64 | 1.2 | 1.0 | 2 |
| drug ineffective | 77 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.